EMA Adopts a New Pharmaceutical Form of Selumetinib By Ogkologos - December 16, 2025 201 0 Facebook Twitter Google+ Pinterest WhatsApp It is associated with an extension to the existing indication Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Low-Pass Genomic Instability Characterisation Assay Identifies Germline Mismatch Repair Deficiency and... October 20, 2022 How a Simple Tool Is Saving Lives of Children with Cancer... February 15, 2024 During No-Visitor Policy at Hospital, Surgeon Comforts Breast Cancer Patient Getting... April 14, 2020 At NCI, A Robust and Rapid Response to the COVID-19 Pandemic April 17, 2020 Load more HOT NEWS ¿Qué deben saber las personas con cáncer sobre el consumo de... Woman Celebrates Beating Cancer By Creating Christmas Tree Mannequins With A... Longitudinal Molecular Profiling of CTCs Captures New Insights in mRCC Jennifer Garner Shared A Video Of Her Mammogram Appointment
